Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty'

(Updated - July 18, 2025 2:19 PM EDT)

Baird analyst Brian Skorney downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Outperform to Neutral with a price target of $15.00 (from $25.00).

The analyst comments "Downgrading on broad, existential uncertainty. We feel like it is too little, too late, but... More

Sarepta Therapeutics (SRPT) PT Lowered to $20 at BofA Securities, 'Safety reports could limit uptake of SRPT’s gene therapies'

BofA Securities analyst Tazeen Ahmad lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $20.00 (from $28.00) while maintaining a Neutral rating.

The analyst comments "A third death following dosing with one of Sareptas gene therapies using the rAAVrh74 vector was reported. The death... More

Morgan Stanley Reiterates Equalweight Rating on Sarepta Therapeutics (SRPT)

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $40.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "Death caused by acute liver toxicity reported in Limb-girdle study. Reports of a third death following treatment with a Sarepta gene therapy has surfaced in a media report (biocentury report), adding to ongoing safety concerns and near-term... More

Goldman Sachs Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $27.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments "Following the second death of a non-ambulatory Elevidys-treated Duchenne muscular dystrophy patient due to acute liver failure (ALF), SRPT has agreed to the FDA's request to include a black box warning for ALF and acute liver injury (ALI), which management believes resolves the ambulatory indication and plans this week to submit the... More

Leerink Partners Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $45.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst comments "Bottom Line: Just when we thought Sarepta's (SRPT, OP) management team was beginning to rebuild their credibility, we learned that a third patient has recently died after treatment with a Sarepta gene therapy (this time it was SRP-9004 in LGMD); a source reported that management knew about this death yesterday when they announced the restructuring, which we find deeply troubling and further undermines credibility. As previously disclosed, two non-ambulatory patients passed... More

Sarepta Therapeutics (SRPT) PT Raised to $28 at TD Cowen

TD Cowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $28.00 (from $24.00) while maintaining a Hold rating.